Your browser doesn't support javascript.
loading
Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation.
Rotem, Asaf; Janzer, Andreas; Izar, Benjamin; Ji, Zhe; Doench, John G; Garraway, Levi A; Struhl, Kevin.
Afiliação
  • Rotem A; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115;
  • Janzer A; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115;
  • Izar B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; and Broad Institute of Harvard and MIT, Cambridge, MA 02139.
  • Ji Z; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115;
  • Doench JG; Broad Institute of Harvard and MIT, Cambridge, MA 02139.
  • Garraway LA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; and Broad Institute of Harvard and MIT, Cambridge, MA 02139.
  • Struhl K; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; kevin@hms.harvard.edu.
Proc Natl Acad Sci U S A ; 112(18): 5708-13, 2015 May 05.
Article em En | MEDLINE | ID: mdl-25902495
ABSTRACT
Colony formation in soft agar is the gold-standard assay for cellular transformation in vitro, but it is unsuited for high-throughput screening. Here, we describe an assay for cellular transformation that involves growth in low attachment (GILA) conditions and is strongly correlated with the soft-agar assay. Using GILA, we describe high-throughput screens for drugs and genes that selectively inhibit or increase transformation, but not proliferation. Such molecules are unlikely to be found through conventional drug screening, and they include kinase inhibitors and drugs for noncancer diseases. In addition to known oncogenes, the genetic screen identifies genes that contribute to cellular transformation. Lastly, we demonstrate the ability of Food and Drug Administration-approved noncancer drugs to selectively kill ovarian cancer cells derived from patients with chemotherapy-resistant disease, suggesting this approach may provide useful information for personalized cancer treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ensaios de Seleção de Medicamentos Antitumorais / Ágar / Antineoplásicos Limite: Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ensaios de Seleção de Medicamentos Antitumorais / Ágar / Antineoplásicos Limite: Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2015 Tipo de documento: Article